Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NYSE:AMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$4.08+0.7%$5.52$2.90▼$11.16$328.48M0.473.38 million shs3.49 million shsAMTAmerican Tower$224.87+0.8%$216.43$172.51▼$243.56$104.41B0.822.50 million shs1.25 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-3.11%-7.95%-41.22%-11.09%-45.93%AMTAmerican Tower-0.02%+0.97%+3.78%+0.11%+4.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.2093 of 5 stars3.41.00.00.03.11.70.6AMTAmerican Tower3.9885 of 5 stars2.64.01.73.13.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.75Moderate Buy$18.20346.08% UpsideAMTAmerican Tower 3.11Buy$240.887.12% UpsideCurrent Analyst Ratings BreakdownLatest MX1, ADR, AMT, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell7/10/2025ALTAltimmuneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $15.007/8/2025AMTAmerican TowerUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$250.00 ➝ $260.006/27/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform6/27/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/19/2025AMTAmerican TowerBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$255.005/1/2025AMTAmerican TowerRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$240.00 ➝ $250.004/30/2025AMTAmerican TowerWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$230.00 ➝ $240.004/30/2025AMTAmerican TowerScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$234.00 ➝ $248.004/30/2025AMTAmerican TowerJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$248.00 ➝ $260.004/30/2025AMTAmerican TowerRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$231.00 ➝ $251.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K16,546.44N/AN/A$1.74 per share2.34AMTAmerican Tower$10.13B10.39$11.68 per share19.26$20.64 per share10.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.260.00N/AN/A-451,200.00%-65.44%-58.43%8/6/2025 (Estimated)AMTAmerican Tower$2.26B$3.8921.2422.491.6517.34%30.20%4.82%7/29/2025 (Estimated)Latest MX1, ADR, AMT, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ALTAltimmune-$0.3006N/AN/AN/A$0.00 millionN/A7/29/2025Q2 2025AMTAmerican Tower$2.59N/AN/AN/A$2.58 billionN/A5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million4/29/2025Q1 2025AMTAmerican Tower$2.41$2.75+$0.34$2.75$2.54 billion$2.56 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AAMTAmerican Tower$6.803.02%N/A174.81%1 YearsLatest MX1, ADR, AMT, and ALT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/15/2025AMTAmerican Towerquarterly$1.703.21%6/13/20256/13/20257/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A15.8515.85AMTAmerican Tower3.430.810.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%AMTAmerican Tower92.69%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%AMTAmerican Tower0.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5081.11 million77.78 millionOptionableAMTAmerican Tower4,691468.14 million467.34 millionOptionableMX1, ADR, AMT, and ALT HeadlinesRecent News About These CompaniesRetirement Planning Co of New England Inc. Trims Stock Position in American Tower Corporation (NYSE:AMT)July 18 at 9:02 AM | marketbeat.comAmerican Tower Corporation (NYSE:AMT) Shares Sold by Sigma Planning CorpJuly 18 at 5:12 AM | marketbeat.comCwm LLC Acquires 1,255 Shares of American Tower Corporation (NYSE:AMT)July 18 at 4:42 AM | marketbeat.comBurling Wealth Partners LLC Sells 3,333 Shares of American Tower Corporation (NYSE:AMT)July 17 at 9:43 AM | marketbeat.comCommerzbank Aktiengesellschaft FI Has $6.98 Million Stock Position in American Tower Corporation (NYSE:AMT)July 17 at 9:14 AM | marketbeat.comKingsview Wealth Management LLC Sells 123,617 Shares of American Tower Corporation (NYSE:AMT)July 17 at 8:46 AM | marketbeat.comMizuho Increases American Tower (AMT) Price Target to $217, Affirms “Outperform”July 16 at 8:24 PM | finance.yahoo.comAmerican Tower Stock Up 19.3% YTD: Will It Continue to Rise?July 16 at 10:25 AM | zacks.comBridgewater Advisors Inc. Takes Position in American Tower Corporation (NYSE:AMT)July 16 at 7:10 AM | marketbeat.comWhittier Trust Co. Lowers Holdings in American Tower Corporation (NYSE:AMT)July 16 at 6:24 AM | marketbeat.comBIP Wealth LLC Decreases Holdings in American Tower Corporation (NYSE:AMT)July 15 at 9:41 AM | marketbeat.comWealthfront Advisers LLC Boosts Holdings in American Tower Corporation (NYSE:AMT)July 15 at 8:19 AM | marketbeat.comLord & Richards Wealth Management LLC Grows Position in American Tower Corporation (NYSE:AMT)July 15 at 7:05 AM | marketbeat.comAmerican Tower Corporation (NYSE:AMT) Shares Sold by Massachusetts Financial Services Co. MAJuly 15 at 6:40 AM | marketbeat.comAmerican Tower Corporation (NYSE:AMT) Shares Sold by Dakota Wealth ManagementJuly 15 at 6:39 AM | marketbeat.comSignaturefd LLC Has $1.74 Million Stock Holdings in American Tower Corporation (NYSE:AMT)July 15 at 5:59 AM | marketbeat.comAmerican Tower Corporation (NYSE:AMT) Shares Purchased by Bogart Wealth LLCJuly 14, 2025 | marketbeat.comSlow Capital Inc. Has $6.22 Million Holdings in American Tower Corporation (NYSE:AMT)July 14, 2025 | marketbeat.comTurtle Creek Wealth Advisors LLC Acquires New Shares in American Tower Corporation (NYSE:AMT)July 14, 2025 | marketbeat.comPittenger & Anderson Inc. Reduces Holdings in American Tower Corporation (NYSE:AMT)July 14, 2025 | marketbeat.comMutual of America Capital Management LLC Sells 1,637 Shares of American Tower Corporation (NYSE:AMT)July 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseInsiders Chase Income and Stability in American Tower—Here’s WhyBy Gabriel Osorio-Mazilli | June 25, 2025View Insiders Chase Income and Stability in American Tower—Here’s WhyMX1, ADR, AMT, and ALT Company DescriptionsAltimmune NASDAQ:ALT$4.08 +0.03 (+0.74%) Closing price 04:00 PM EasternExtended Trading$4.10 +0.02 (+0.49%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.American Tower NYSE:AMT$224.87 +1.83 (+0.82%) Closing price 03:59 PM EasternExtended Trading$224.20 -0.66 (-0.30%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.American Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 224,000 communications sites and a highly interconnected footprint of U.S. data center facilities. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
